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ABSTRACT (Word-count 192) 
Non-erosive reflux disease (NERD) is a common condition and the most frequent phenotype 
of GERD. NERD is extremely heterogeneous and includes patients with negative endoscopy, but 
abnormal esophageal acid exposure and/or positive reflux-symptom association analysis 
(hypersensitive esophagus). This segregation is only possible thanks to the use of impedance-pH 
monitoring. Indeed, weakly acidic reflux represents one of the most frequent cause of refractory 
symptoms in patients evaluated off-anti-secretory therapy and, more importantly, during anti-
secretory drug treatment. Patients with heartburn who do not have any type of reflux underlying 
their symptoms (functional heartburn) must be excluded from the category of GERD. The 
drawbacks of impedance-pH are mainly due to the day-to-day variability of the test and by the fact 
that the accuracy of the symptom-reflux correlation scores is often far from being perfect. Some 
histopathological characteristics, as dilated intercellular spaces, can be helpful to distinguish 
patients with NERD by esophageal biopsies. As to the outcome, patients with NERD in whom acid 
is the main pathogenetic factor respond successfully to PPI therapy, while those with hypersensitive 
esophagus to weakly acidic reflux could be treated with reflux inhibitors or surgery, although 
further controlled studies are required.  
  
Definition of NERD and sub-groups 
Heartburn, or retrosternal burning, is a typical symptom of gastroesophageal reflux disease 
(GERD) that frequently affects a large part of population (10%-20%) in Western countries, 
interfering significantly with the quality of life of many patients.1 
For many years, erosive reflux disease has been considered the more common manifestation 
of GERD, nevertheless, in the past decade it has been realized that erosive reflux disease represents 
the minority of patients with GERD (~30%), whereas the majority of them (~70%) are included in 
the non-erosive reflux disease (NERD) phenotype, characterized by the presence of typical reflux 
symptoms without any esophageal mucosal lesion visible at endoscopy.2, 3 
Pathophysiological studies carried out with 24-hour esophageal multichannel intraluminal 
impedance–pH testing (MII-pH) have demonstrated that patients with NERD phenotype are 
markedly heterogeneous and can be subdivided into several well-defined subgroups (after excluding 
eosinophilic esophagitis, EoE and primary esophageal motor disorders). Currently, the NERD 
definition includes patients with negative endoscopy but abnormal esophageal acid exposure 
(AET).3-7 
Further, in the NERD population, we can include patients with negative endoscopy and 
normal pathophysiological testing (pH-metry/MII-pH), both for AET and total number of reflux 
events, but with these latter variables temporarily correlated with symptoms (Hypersensitive 
esophagus, HE).7 The correlation between symptoms and reflux events is commonly defined by 
means of symptom index (SI positive if > 50%) and symptom association probability (SAP, 
positive if > 95%).6 Patients may be hypersensitive to both acid and/or non-acid reflux events.4, 8, 9 
Patients with heartburn refractory to proton pump inhibitors (PPIs), who show negative endoscopy, 
normal AET and number of refluxes and no correlation between symptoms and reflux, should be 
considered as patients with functional heartburn (FH)4, 6, 7, 10 and should not be considered and 
treated as GERD patients (i.e. stopping any kind of anti-secretory therapy and not undergoing anti-
reflux surgery). Accordingly, the last iteration of Rome criteria defined FH as  “chronic retrosternal 
burning, discomfort or pain refractory to optimal antisecretory therapy in the absence of GERD, 
histopathologic mucosal abnormalities, major motor disorders, or structural explanations.7 In line 
with this definition, Savarino et al.10 demonstrated the added value of MII-pH in distinguishing 
patients with GERD from those affected by FH, by showing a 10% diagnostic gain with this 
technique. Similar results were obtained in some studies performed both “off PPI therapy”8, 11-14 
(10-15% diagnostic gain) and “on PPI therapy”11, 12, 15, 16 (20-40% diagnostic gain) with MII-pH 
testing. Overall, the added values and the clinical application of impedance monitoring should help 
the clinicians to correlate an increased number of symptoms with reflux events, thus increasing the 
number of patients with reflux disease and reducing the rate of patients with FH. 
 
Clinical characteristics 
The positive or negative response of patients with heartburn to PPI therapy is an empiric 
criterion, which can include or exclude from the definition of GERD those patients who complain 
of heartburn and do not have an objective demonstration of the presence or absence of gastro-
esophageal reflux. However, it has been estimated that 25%-40% of patients complaining of 
heartburn continue to present symptoms despite daily PPI use and that there is a large group of 
patients with functional disorders rather than GERD who may respond to PPI due to a placebo 
effect.5, 17 Previous studies have underlined this important limitation, which affects the diagnostic 
accuracy of the PPI test.18, 19 In particular, Bytzer et al.20 carried out a study in a sample of well-
defined primary care patients with suspected GERD, and demonstrated the limited ability of a PPI 
trial to identify patients with GERD, using endoscopy, esophageal pH-metry and reflux disease 
questionnaires as reference standard. Presence or absence of gastro-esophageal reflux during 
barium esophagography does not correlate with incidence or extent of reflux observed during MII-
pH monitoring and it is not of value for the diagnosis of GERD.19, 21 
A symptom-based approach using a questionnaire (GERDQ) does not always confirm 
GERD diagnosis.22, 23 Multiple studies have demonstrated that patients with objective evidence of 
reflux tend to be older, male, and smokers in comparison to patients with FH.24-27 Increased body 
mass index (>25 kg/m2) is also associated with PPI failure in patients with acid reflux compared 
with those patients with HE or FH.27-29 Further, there are several evidences suggesting a strong 
association between FH and other functional disorders such as functional dyspepsia and/or irritable 
bowel syndrome, emphasizing the hypothesis of a unique “whole gut” GI disorder.30-32  
However, currently, demographics do not reliably distinguish subgroups of patients 
suffering from heartburn.25, 33 Understanding the epidemiology and pathogenesis of patients with 
FH may allow early recognition of these patients and could help to anticipate and avert therapeutic 
failure.34 
 
MII-pH diagnosis and different GERD phenotypes 
Patients often undergo extensive functional testing to evaluate heartburn if there is 
inadequate response to optimal acid suppressive therapy, as this approach seems to be useful in 
differentiating FH from refractory acid reflux. To note, optimal acid therapy is not well-defined in 
the literature. In the setting of objective acid testing, an effective therapy may be considered the 
adequate control of acid assessed by a functional examination. However, a simple and more often 
used definition for optimal acid suppression is the lack of symptoms in response to acid suppression 
(defined as twice a day proton pump inhibition).6, 35 
The complete chemical nature of reflux can be detected neither by traditional esophageal 
pH-metry nor by the catheter-free Bravo™ system,36 but the advent of 24 h MII-pH testing has 
enabled differentiation of acid (reflux with pH<4) from weakly acidic (4<pH<7) or weakly alkaline 
reflux (pH>7).37 Indeed, reflux of gastric content into the esophagus is a physical event that has 
been evaluated for long time only by means of techniques able to obtain information on the 
chemical component of refluxate. The MII-pH was an innovative technique that provided a detailed 
characterization of each reflux event including chemical (acid, weakly acidic/alkaline reflux) and 
physical properties (liquid, mixed, gas).37, 38 In the last decade, it has been shown that nonacid 
reflux (weakly acidic and weakly alkaline reflux events) represents the majority of reflux episodes 
in patients with GERD on PPI therapy.39, 40 Indeed, the total number of reflux episodes is not 
affected by acid suppressive therapy, and weakly acidic reflux accounts for approximately 90% of 
all reflux episodes in patients on PPIs, thus representing a potential mechanism underlying the 
failure of PPI treatment in patients with reflux-related symptoms.12, 15 Further, the assessment of 
both acid and non-acid reflux correlation with symptoms may allow us to better select patients who 
would benefit from anti-reflux surgery or an endoscopic anti-reflux procedure.41 
However, all of the available tests for GERD diagnosis have some limitations. The 
drawbacks of MII-pH are mainly due to the day-to-day variability of the test.42-44 Additionally, the 
reflux-symptom correlation in patients with GERD who do not respond to PPI therapy is actually 
calculated by the symptom index (SI) or symptom association probability (SAP), although their 
validity is still uncertain.45, 46 Unfortunately, symptoms may not occur during 24-hour reflux 
monitoring. Moreover, the accuracy of patients in symptom recording is often far from perfect. As a 
consequence, SAP/SI may be negative even in several patients with erosive reflux disease (ERD).16, 
47-49 Therefore, in pH-negative patients a positive SAP/SI indicates reflux-related heartburn,4, 50 but 
a negative SAP/SI does not exclude GERD; indeed, patients with heartburn may respond to PPI 
therapy despite normal MII-pH findings.51 Accordingly, Zerbib et al.52 reported that MII-pH results 
were not always able to predict the response to PPIs in patients with typical reflux-related 
symptoms, when the test was performed off PPI therapy. 
Recently, the ability of MII-pH testing in better understanding GERD pathophysiology has 
improved by means of new parameters, such as the post-reflux swallow-induced peristaltic wave 
(PSPW) index, which indicates the efficacy of esophageal clearance,47 and the baseline impedance 
values, which indicate lack of integrity in the esophageal mucosa.16, 39, 47, 53, 54 PSPW index has been 
shown to be lower in patients with abnormal AET, compared to healthy volunteers (HVs) or FH.47 
Moreover, this parameter was not altered after medical or surgical therapy.55 Further, Kessing et 
al.55 described lower values of baseline impedance levels in the distal esophagus of patients with 
abnormal esophageal AET, compared to HVs. Recently, many studies standardized the 
measurement of baseline impedance by calculating the mean nocturnal baseline impedance (MNBI) 
across three 10-min periods between 1 AM and 3 AM, away from daytime esophageal physiologic 
activity.48, 51, 56 The most relevant advantages regarding both the MBNI and PSPW index have been 
recently published by Frazzoni et al.48 The authors showed a gradient behaviour of them across 289 
GERD patients and 50 healthy controls, being both parameters worse in erosive esophagitis 
compared with NERD and healthy controls. The diagnostic yield of both parameters was greater 
than that of increased AET, total reflux events, and bolus exposure time in both erosive esophagitis 
and NERD. Furthermore, MNBI and PSPW index make pathophysiologic sense, and certainly 
deserve a chance in redeeming the clinical value of ambulatory MII-pH testing.57 
There are still others information that could be caught from a more in deep analysis of MII-
pH tracing such as the role of bolus contact time in improving GERD diagnosis 58 or gas and mixed 
reflux or supragastric belching in increasing symptom perception.59, 60 Further, the role of this 
technique in the management of patients with extraesophageal GERD has been partially 
investigated.61-67 
 
Weakly acidic reflux and refractory heartburn 
The Porto consensus report provided a detailed nomenclature for reflux patterns detected by 
MII- pH monitoring.37 An impedance-detected reflux is defined as acid when the esophageal pH 
falls to < 4, or when reflux occurs with the esophageal pH already < 4. When the esophageal pH 
falls by ≥ 1 unit, but remains > 4, it is considered “weakly acidic reflux.” 
The prevalence of weakly acidic reflux (WARs) in refractory GERD depends on the way 
reflux monitoring is performed. Although several WARs episodes can be detected during 24-hour 
MII-pH monitoring “off” PPI, this type of refluxate becomes particularly significant during studies 
“on” PPI.12, 15, 68, 69 First of all, Vela et al.69 used stationary MII-pH monitoring to compare 3-h 
postprandial recordings of the same subject “on” and “off” PPI. The antisecretory treatment 
provoked no reduction in the total number of reflux events, but there was a shift in the refluxate’s 
pH from acidic to weakly acidic. Heartburn was replaced by regurgitation, which became the 
predominant symptom in these patients. Similarly and by means of the more reliable 24-hour pH-
impedance monitoring, Frazzoni and co-workers showed that WARs are the predominant reflux 
events in patients evaluated on-PPI.16, 39, 54 
Studies in patients with refractory GERD showed that WARs could be associated with 30%-
40% of symptoms.12, 15 16, 54 In another study Zerbib et al,70 observed that in a group of patients with 
refractory heartburn WARs were associated to both heartburn and regurgitation in patients 
evaluated on double dose PPI therapy. The role of WARs in patients with typical refractory 
symptoms has been studied, almost always, in patients on PPIs. Few but intriguing data have been 
reported on WARs evaluated in patients off-therapy and it was confirmed that this type of chemical 
reflux can be associated with both heartburn and regurgitation.49, 71, 72 
A prospective study in well selected PPI responder and non-responder NERD patients, in 
whom MII-pH was performed both off an on-PPIs,73 showed that WAR accounted for 
approximately 30% of symptomatic refluxes both in non-responder and in responder patients 
whereas an overall increased number of reflux episodes and an enhanced sensitivity to all episodes 
could predict treatment failure. Comparable finding were reported in consecutive refractory patients 
- 50% of them affected by erosive esophagitis - undergone laparoscopic fundoplication 16 and 
repeated MII-pH monitoring performed on PPIs before treatment and off PPIs at follow up. In that 
series, the 3-year outcome assessment revealed that decrease of the abnormal number of all reflux 
episodes (also due to a decrease of WARs), normalization of acid exposure and of SAP/SI were 
associated with a sustained symptom remission. 
The mechanisms by which WARs can provoke persistence of symptoms remain 
controversial, as several factors have been proposed: (1) esophageal distension by increased reflux 
volume,70 (2) persistent impairment of esophageal mucosa due to weakly acidic reflux containing 
bile acids,74 (3) the proteolytic activity of pepsins that is maintained up to pH 6 75 and healing of 
mucosal breaks occurs through reparative processes that are inhibited at pH 6.5 and abolished at pH 
3.0,75 (4) esophageal hypersensitivity to non-acid components of gastric contents either when gas is 
present in the refluxate or after esophageal sensitization due to an acid reflux 76, 77 and (5) reduced 
esophageal chemical clearance.78 Once refluxate has entered the esophagus the main defense 
against persistence of mucosal damage is removal of the noxious agents as quickly as possible: 
indeed, defective chemical clearance of WARs, which represents the vast majority of reflux events 
in PPI-refractory GERD, has a key role in the pathogenesis of PPI-refractory reflux esophagitis.47, 78  
By the way, there is no doubt that WARs can be one of the underlying mechanisms of 
refractory GERD. Indeed, a cause-and-effect relationship between WARs and PPI-refractory 
heartburn/regurgitation has been shown in some prospective observational studies addressing post 
surgical outcome in PPI-refractory typical GERD.16, 54 These studies well evidenced that WARs 
might be considered the major determinant of typical GERD-related symptoms in PPI-refractory 
patients. Anyway, future prospective studies should be addressed to confirm these data in a larger 
series of patients. 
 
Histopathology changes and mucosal barrier integrity in NERD subgroups 
The integrity of the mucosal epithelial barrier is of great importance to prevent pathologic 
consequences of reflux, and can be overcome in the disease state (whether erosive or non-erosive). 
So, it is of relevance to discuss the structures responsible for maintenance of mucosal integrity. 
The pre-epithelial defense consists of a small water layer with limited buffering capacity, 
presumably due to the presence of bicarbonate derived from swallowed salivary fluid and from 
secretions of esophageal submucosal glands.79 In patients with esophagitis there is a clear breach in 
this barrier allowing components of the refluxate to reach the nociceptors in the lamina propria.79 
Acid and acid-pepsin initially attack and damage the intercellular junctions, thus resulting in an 
increase in para-cellular permeability, reflected morphologically by the presence of dilated 
intercellular spaces.80 
From a diagnostic point of view, esophageal biopsies might be helpful to identify patients 
with histological signs of GERD. Further, it is relevant to underline that the addition of esophageal 
biopsies as an adjunct to an endoscopic examination has been re-emphasized because of the 
progressively increased detection of eosinophilic esophagitis (EoE). Many clinicians routinely take 
esophageal biopsies in patients with reflux-type symptoms to search for EoE in the setting of an 
endoscopy that does not reveal erosive changes.81 
Histological examination of esophageal biopsies may help in distinguishing patients with 
NERD from FH, as dilated intercellular spaces can be a microscopic marker of reflux and 
esophageal damage frequently associated with NERD and only rarely with FH.82 The presence of 
dilated intercellular spaces may also predict a non-response to acid suppression.83 Using light 
microscopy (LM), it is possible to combine multiple histological alterations denoting the presence 
of microscopic esophagitis (ME), such as basal cell hyperplasia, papillae elongation, and DIS.84-86 
Zentilin et al.85 proposed a histological score able to discriminate between GERD and 
controls with a positive predictive value of 97% and a negative predictive value of 46%. 
It has been also hypothesized that there is a good correlation between DIS in the esophageal 
epithelium of both ERD and NERD patients and the presence of heartburn.87 Recently, Savarino et 
al.88 demonstrated the lack of microscopic esophagitis (ME) in the esophageal distal biopsies of FH 
patients, suggesting a limited role of these histological abnormalities in symptom generation in 
them. ME can be considered as an accurate and reliable diagnostic marker for distinguishing FH 
patients from GERD patients and has the potential to be used to guide the correct therapy. 
Fiocca et al.89 developed consensus guidelines for histologic recognition of ME in patients 
with GERD and proposed several criteria, which achieved high levels of agreement when assessed 
independently by 5 pathologists. 
Recently, Kandulski et al.90 confirmed that esophageal biopsies are useful to differentiate 
NERD from FH, especially in patient with refractory heartburn. The same authors showed that low 
levels of baseline impedance (detected with 24-h MII-pH) are associated with increased exposure to 
acid and dilation of intercellular spaces, indicating a strong correlation between esophageal mucosal 
impairment and baseline impedance.91 
However, these histological alterations are not still adequately sensitive and specific to be 
used in a diagnostic algorithm, and so far routine esophageal biopsies as a means of making a sound 
diagnosis of FH are not recommended.  
 
Aerophagia, gas reflux and supragastric belching in pathophysiology of NERD 
Aerophagia is a condition of excessive air swallowing, which goes to the stomach. 
Pouderoux et al.92 observed, by means of ultrafast computerized tomography, a substantial 
aerophagia (8-32mL of air) during transit of a swallowed bolus through the esophagus and a partial 
bolus separation with air preceding fluid. Bravi et al.93 demonstrated that PPI non-responder 
patients with GERD swallowed more air at mealtime than those who respond to PPI treatment and 
also have more reflux episodes that contain gas. The authors concluded that air swallow combined 
with mucosal sensitization could affect perception of symptoms.  
Gastric belching (frequent gas-reflux events during MII-pH 24-h) is the escape of swallowed 
intragastric air that enters the esophagus during a transient lower-esophageal sphincter relaxation 
(TLESR).94 Gastric belches occur 25 to 30 times per day and are physiological, involuntary and 
controlled entirely by reflexes. Belching does not seem to facilitate acid reflux in healthy subject.95 
On the other hand, the presence of gas into the refluxate enhances reflux perception, is frequently 
associated with proximal extent of reflux and occurs more frequently in patients who do not 
respond to acid suppressive treatment.71, 77, 93, 96 
In supragastric belches the air does not originate from the stomach but is ingested 
immediately before it is expelled again.97 
Supragastric belches are not a reflex but, instead, are the result of human behavior. Studies 
with simultaneous impedance monitoring and high-resolution manometry reveal the underlying 
mechanism of this behavior: a contraction of the diaphragm creates a negative pressure in the 
thoracic cavity and the esophagus, subsequent relaxation of the UES, resulting in inflow of air into 
the esophagus.98 It is unclear what causes supragastric belching and what causes patients to start 
this behavior. Some patients report that initially they belched purposefully to relieve a sensation of 
bloating or abdominal discomfort but that with time they lost control of the belching. Many patients 
stop belching during speaking and sleeping; it has been shown that distraction also reduces the 
frequency of belching,97 whereas putting attention to their belching behavior usually results in an 
increase in belching frequency.97 Recently, Koukias et al.60 described 100/2950 patients, over a 4 
years period, with supragastric belching that were associated more frequently with pathological acid 
exposure and esophageal hypomotility.  
Speech therapy has been proposed in a recent pilot study including 11 patients and resulted 
to be beneficial.99 Similar positive results have been reported with behavioral therapy in another 
study.100 Baclofen has also been applied with success in a small open label study.101 
 
Medical and surgical treatment in NERD, hypersensitive esophagus and functional heartburn 
Patients presenting with symptoms suggestive of reflux disease are often empirically treated 
with lifestyle advices and acid suppressive drugs, including PPIs.102-105 When patients do not 
respond to standard therapy, endoscopic and functional testing is performed to challenge the initial 
diagnosis and to investigate the reasons of treatment refractoriness. While the presence of erosive 
esophagitis confirms the diagnosis, a negative endoscopy cannot be used to rule out reflux disease, 
as a substantial part of GERD patients do not have any abnormalities seen on endoscopy 
(NERD).106, 107 
In most clinical trials, NERD patients are defined only by the presence of typical reflux 
symptoms and negative endoscopy. However, without appropriate functional testing it is difficult, if 
not impossible, to distinguish between FH, functional dyspepsia, and true NERD. Thus, the 
heterogeneity of the trial participants across studies could cause underestimation of the response 
rates to PPI treatment in NERD. Indeed, in a recent meta-analysis, Weijenborg et al. observed that 
in well-defined NERD patients (diagnosed by means of endoscopy and pathophysiological tests), 
the estimated complete symptom response rate after PPI therapy is comparable to the response rate 
in patients with ERD. In this paper the authors concluded that the previously reported low response 
rate in studies with patients classified as NERD was likely the result of inclusion of patients with 
upper gastrointestinal symptoms that did not have reflux disease.108 
Previously, Fass et al.109 observed a direct and strong correlation between acid exposure 
time and the positive response rate to omeprazole (40 mg in the morning and 20mg in the evening). 
Zerbib et al.52 described that patients with either positive symptom–reflux association 
analysis or AET>5% were more frequently associated with a positive response to PPI therapy. 
However, the main finding of this study was that performing the multivariate analysis, the only 
factors associated with inadequate response to PPI were BMI ≤25 kg/m2 and the presence of 
functional dyspepsia or irritable bowel syndrome symptoms. Patel et al.110 observed that only acid-
based reflux parameters (total AET and AET>4.0%) offer greater value over impedance-based 
nonacid-reflux parameters (total reflux events and bolus exposure time) in predicting symptomatic 
responses to PPI therapy.  
Controlling heartburn in patients with NERD can also be achieved with antacid or alginate 
compounds. Many clinical trials have demonstrated the benefit of these drugs, which continue to 
have a role in quickly relieving typical reflux symptoms in both NERD and erosive reflux 
disease.111-117 However, these over-the-counter drugs need multiple doses during the day, because 
of their short duration of action. Sodium alginate is a polysaccharide derived from seaweed. It binds 
water to form a viscous gum that floats in the proximal stomach, thereby separating the acid pocket 
from the distal esophagus.118 Some commercially available alginate preparations also contain an 
antacid. Sodium alginate might have the theoretical advantage of blocking both acid and WARs on 
the basis of the mechanical formation of a raft floating above gastric secretions, but its effect on the 
latter kind of reflux was not confirmed in a study using MII–pH testing.119 As above-mentioned, 
most reflux episodes happen during TLESRs, and these can be inhibited pharmacologically. The γ-
aminobutyric acid (GABA)B-receptor agonist baclofen reduces the incidence of TLESRs and reflux 
episodes. Vela et al.120 have shown that baclofen induces a reduction of total amount of reflux 
events and contributes to improve the symptoms complained of by patients with reflux. On the 
other hand, this drug is not suitable for treatment of GERD because of its mainly neurologic central 
side-effects.121  Unfortunately, the development of new drugs of this type with less severe adverse 
events than baclofen has been stopped, because of poor efficacy.122 
An additional therapeutic option might be surgery that should be considered for patients 
with proven GERD and for those patients with weakly acidic reflux events.16, 123, 124 
Five-year results of a randomised European trial comparing maintenance PPI treatment 
(esomeprazole) with laparoscopic Nissen fundoplication125 showed that the remission rate did not 
differ between the two therapeutic strategies. However, at 5 years, acid regurgitation was more 
prevalent in the PPI group than in the fundoplication group. 
Several uncontrolled trials have shown that fundoplication is able to control symptoms 
related to both acid and WARs16, 41, 54, 126, 127 In particular, Broeders et al.126 have demonstrated that 
patients with normal AET and positive symptom association (HE patients) might benefit from 
fundoplication as well as patients with abnormal AET, although an important limitation of this 
study should be reported in that about 40% of the HE patients had prior evidence of erosive 
esophagitis at endoscopy (i.e. not affected by HE per definition). Similarly, Patel et al.128 showed 
that anti-reflux medical and surgical therapy may improve symptoms in hypersensitive patients, in 
well-defined settings. Bredenoord et al.129 confirmed that fundoplication is able to reduce the 
abnormal levels of both chemical types of reflux.  Patel et al.130 demonstrated in a large series of 
patients, after a 40-month follow-up period, that the response to laparoscopic anti-reflux therapy 
was consistent in patients selected by means of a MII-pH performed off-therapy. The authors 
showed that abnormal AET and the symptom-reflux association SAP consistently predicted 
symptomatic outcome in a multivariate analysis. 
Few data are available regarding characteristics of the refluxate, such as the presence of 
pepsin and bile acids that may contribute to symptom perception.131 In this review we focused that 
WARs events can cause not only regurgitation but also heartburn 5, 71 and patients with 
symptomatic non-acid (weakly acidic) reflux on PPI treatment should be considered good 
candidates for anti-reflux surgery. 
Conclusions 
Gastroesophageal reflux disease is a very common condition. Heartburn and regurgitation 
are the symptoms of the typical reflux syndrome. Reflux characteristics, other than acidity, such as 
the presence of WARs and presence of pepsin may also contribute to symptom perception. The 
cornerstone for treatment of GERD-related symptoms is acid suppression with PPIs. In tertiary care 
center it is more frequent running into patients unresponsive to acid suppressive treatment. The lack 
of response to a sustained acid inhibition suggests that the symptoms are not due to reflux or, 
alternatively, that they are reflux-related but PPI-unresponsive. Pathophysiological diagnosis of 
GERD should be performed preferably by means of combined pH-impedance measurement. 
Patients should be recommended to accurately record symptoms to obtain the best information from 
symptom-reflux correlation scores. Up and coming parameters obtained from impedance and pH 
tracings as well as the presence of gas, aerophagia and supragastric belching should be considered, 
particularly when patients fail to record symptoms before considering functional diagnosis. Future 
studies are needed on these topics. 
When NERD patients have been well characterized, PPI treatment as well as antireflux 
surgery can be considered effective in them. It has been shown that a proportion of patients with 
reflux hypersensitivity can improve with antireflux surgery, especially if regurgitation is the main 
symptom and some structural disruption at the esophago-gastric junction may be documented.132-134. 
At present functional upper GI symptoms are an exclusion criterion for antireflux surgery. 
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